Cryoport, Inc. logo CYRX - Cryoport, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 14
HOLD 4
SELL 0
STRONG
SELL 0
| PRICE TARGET: $15.25 DETAILS
HIGH: $17.00
LOW: $12.00
MEDIAN: $16.00
CONSENSUS: $15.25
UPSIDE: 8.93%

Stock News

Cryoport Reports First Quarter 2026 Financial Results

Cryoport Reports First Quarter 2026 Financial Results

First quarter revenue grew 16% year-over-year to $47.8 million Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programs Life Sciences Services revenue increased 18% year-over-year, led by 21% growth in BioStorage/BioServices  Life Sciences Products revenue increased 15% year-over-year, driven by strong demand for cryogenic systems Supporting a record 766 global clinical trials and 21 commercially approved CGTs as of March 31, 2026 Company raises full-year revenue guidance to $192 million - $196 million NASHVILLE, Tenn., May 4, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its first quarter (Q1) of 2026.

May 04, 2026 12:05 PM • prnewswire.com
CryoPort, Inc. (NASDAQ:CYRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

CryoPort, Inc. (NASDAQ:CYRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

CryoPort, Inc. (NASDAQ: CYRX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have given a buy recommendation to the

Mar 22, 2026 10:23 PM • defenseworld.net
Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance Life Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025 Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025 Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y) NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its fourth quarter (Q4) and year ended (FY) December 31, 2025.

Mar 03, 2026 11:05 AM • prnewswire.com
Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close.

Feb 17, 2026 03:00 AM • prnewswire.com
Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

Self-Sustaining Fusion® 800 Series  Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space Environments NASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced the launch of the MVE Fusion® 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology.

Feb 11, 2026 03:30 AM • prnewswire.com
CryoPort (NASDAQ:CYRX) vs. Royal Mail (OTCMKTS:ROYMY) Head-To-Head Contrast

CryoPort (NASDAQ:CYRX) vs. Royal Mail (OTCMKTS:ROYMY) Head-To-Head Contrast

CryoPort (NASDAQ: CYRX - Get Free Report) and Royal Mail (OTCMKTS:ROYMY - Get Free Report) are both transportation companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation. Institutional and Insider Ownership 92.9% of CryoPort shares are

Jan 12, 2026 09:14 PM • defenseworld.net

Price Targets